Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature
DOI:
https://doi.org/10.2340/00015555-3840Keywords:
lichen planus, melanoma, pembrolizumab, immune-related adverse event, anti-PD-1, anti-PD-L1Abstract
Abstract is missing (Short communication)
Downloads
References
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2019. Eur J Cancer 2020; 126: 159-177.
DOI: https://doi.org/10.1016/j.ejca.2019.11.015
FDA approval timeline of active immunotherapies. Cancer Research Institute; 2020. [Date accessed September 30, 2020] Available from: https://www.cancerresearch.org/scientists/immuno-oncology-landscape/fda-approval-timeline-of-active-immunotherapies.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789-1801.
DOI: https://doi.org/10.1056/NEJMoa1802357
Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis 2020; 7: 359-369.
DOI: https://doi.org/10.1016/j.gendis.2020.02.002
Squibb BM. CheckMate -577, a phase 3 trial evaluating opdivo (nivolumab) as adjuvant therapy for patients with resected esophageal or gastroesophageal junction cancer, meets primary endpoint of disease-free survival 2020. [Date accessed September 30, 2020] Available from: https://news.bms.com/news/details/2020/CheckMate--577-a-Phase-3-Trial-Evaluating-Opdivo-nivolumab-as-Adjuvant-Therapy-for-Patients-with-Resected-Esophageal-or-Gastroesophageal-Junction-Cancer-Meets-Primary-Endpoint-of-Disease-Free-Survival/default.aspx.
Squibb BM. Opdivo (nivolumab) significantly improves disease free-survival vs. placebo as adjuvant therapy for patients with high-risk, muscle-invasive urothelial carcinoma in phase 3 CheckMate -274 Trial 2020. [Date accessed September 30, 2020] Available from: https://news.bms.com/news/corporate-financial/2020/Opdivo-nivolumab-Significantly-Improves-Disease-Free-Survival-vs.-Placebo-as-Adjuvant-Therapy-for-Patients-with-High-Risk-Muscle-Invasive-Urothelial-Carcinoma-in-Phase-3-CheckMate--274-Trial/default.aspx.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol 2016; 28: 254-263.
DOI: https://doi.org/10.1097/CCO.0000000000000290
Schwager Z, Stern M, Cohen J, Femia A. Clinical epidemiology and treatment of lichen planus: a retrospective review of 2 tertiary care centers. J Am Acad Dermatol 2019; 81: 1397-1399.
DOI: https://doi.org/10.1016/j.jaad.2019.04.027
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19: 345-361.
DOI: https://doi.org/10.1007/s40257-017-0336-3
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83: 1255-1268.
DOI: https://doi.org/10.1016/j.jaad.2020.03.132
Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018; 10: 1758835918764628.
DOI: https://doi.org/10.1177/1758835918764628
Levine O, Devji T, Xie F. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. Hum Vaccin Immunother 2017; 13: 1765-1767.
DOI: https://doi.org/10.1080/21645515.2017.1322241
de Lorenzi C, Andre R, Vuilleumier A, Kaya G, Abosaleh M. Bullous lichen planus and anti-programmed cell death-1 therapy: case report and literature review. Ann Dermatol Venereol 2020; 147: 221-227.
DOI: https://doi.org/10.1016/j.annder.2019.07.008
Cortellini A, Buti S, Agostinelli V, Bersanelli M. A systematic review on the emerging association between the occurrence of immune-related adverse events and clinical outcomes with checkpoint inhibitors in advanced cancer patients. Semin Oncol 2019; 46: 362-371.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Anne-Charlotte Niesert, Anne Guertler, Olga Schutti, Laura Engels, Michael Flaig, Lars E. French, Max Schlaak, Markus Reinholz
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
